ESMO World Congress on Gastrointestinal Cancer | Conference

Nivolumab Spurs Encouraging Responses in Metastatic Anal Cancer

July 2nd 2016

The first prospective study to investigate the use of immunotherapy in patients with squamous cell carcinoma of the anal canal demonstrated promising results following treatment with nivolumab.

FGFR Inhibitor ARQ-087 Safe, Effective in Early Cholangiocarcinoma Study

July 1st 2016

Treatment with ARQ-087 demonstrated promising signs of clinical activity with a manageable safety profile for patients with FGFR2 fusion-positive advanced and/or metastatic intrahepatic cholangiocarcinoma.

SIRT Improves Depth of Response in mCRC Patients With Liver Mets

July 1st 2016

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

Adding IMAB362 to Chemo Extends Survival in Advanced Gastric Cancer

July 1st 2016

IMAB362, a novel chimeric IgG1 backbone antibody highly specific for CLDN18.2, extended median overall survival by 4.8 months when added to standard chemotherapy in patients with advanced gastric cancer.

Dr. Navesh K. Sharma on Older Patients Tolerating Internal Radiation

July 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses that age should not be a deciding factor in giving internal radiation to patients with liver cancer.

Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment

July 1st 2016

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

Dr. Adam Bass on the Origins of Different Gastric Tumor Types

July 1st 2016

Dr. Adam Bass, MD, Dana-Farber Cancer Institute, discusses the causes for different types of gastric cancer.

Outcomes Similar With Chemo Only Versus Chemoradiation for Gastric Adenocarcinoma

July 1st 2016

Patients with stage Ib-IVa resectable gastric adenocarcinoma undergoing surgery with curative intent had similar survival outcomes regardless of whether they received chemotherapy or chemoradiotherapy after surgery.

Dr. Eileen O'Reilly on Factors to Consider in Pancreatic Cancer Treatment

June 30th 2016

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

Daniel Sargent on International Collaboration for Colon Cancer Research

June 30th 2016

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

QOL Sustained When Adding MM-398 to Standard Care in Pancreatic Cancer

June 30th 2016

Adding MM-398 (irinotecan liposome injection; nal-IRI; Onivyde) to 5-fluorouracil and leucovorin had no negative effect on quality of life while significantly improving overall survival in patients with metastatic pancreatic cancer.

Dr. John Marshall on Differentiating Squamous and Adenocarcinoma in GI Cancers

June 30th 2016

John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the difference between squamous and adenocarcinoma in esophageal and gastric cancer.

Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC

June 29th 2016

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Second-Line Regorafenib Boosts Survival in HCC

June 28th 2016

Second-line treatment with regorafenib (Stivarga) improved overall survival by 2.8 months compared with placebo for patients with unresectable hepatocellular carcinoma who progressed on sorafenib (Nexavar).

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

July 16th 2015

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

July 15th 2015

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Dr. Argilés on BRAF-Mutations in Colorectal Cancer

July 10th 2015

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients

July 8th 2015

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

Dr. Vandecaveye on Diffusion MRI for Tumor Differentiation

July 8th 2015

Vincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.

Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma

July 7th 2015

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

NEXT PAGE
PREVIOUS PAGE